Rimiterol

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Name

Rimiterol

Accession Number

DB13559

Description

Not Available

Type

Small Molecule

Groups

Experimental

Structure

Similar Structures

Weight: Average: 223.272
Monoisotopic: 223.120843411
Chemical Formula: C₁₂H₁₇NO₃

Synonyms

Rimiterol

Pharmacology

: Accelerate your drug discovery research with the industry’s only fully connected ADMET dataset, ideal for:
Machine Learning
Data Science
Drug Discovery
Accelerate your drug discovery research with our fully connected ADMET dataset
Learn more
Indication: Not Available
Contraindications & Blackbox Warnings: Contraindications & Blackbox Warnings
With our commercial data, access important information on dangerous risks, contraindications, and adverse effects.
Learn more
Our Blackbox Warnings cover Risks, Contraindications, and Adverse Effects
Learn more
Pharmacodynamics: Not Available
Mechanism of action: Not Available
Absorption: Not Available
Volume of distribution: Not Available
Protein binding: Not Available
Metabolism: Not Available
Route of elimination: Not Available
Half-life: Not Available
Clearance: Not Available
Adverse Effects: Reduce medical errors
and improve treatment outcomes with our comprehensive & structured data on drug adverse effects.
Learn more
Reduce medical errors & improve treatment outcomes with our adverse effects data
Learn more
Toxicity: Not Available
Affected organisms: Not Available
Pathways: Not Available
Pharmacogenomic Effects/ADRs: Not Available

Interactions

Drug Interactions

This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.

Drug	Interaction
Integrate drug-drug interactions in your software
Acebutolol	The therapeutic efficacy of Rimiterol can be decreased when used in combination with Acebutolol.
Aceclofenac	The risk or severity of hypertension can be increased when Aceclofenac is combined with Rimiterol.
Acemetacin	The risk or severity of hypertension can be increased when Rimiterol is combined with Acemetacin.
Acetylsalicylic acid	The risk or severity of hypertension can be increased when Acetylsalicylic acid is combined with Rimiterol.
Aclidinium	The risk or severity of Tachycardia can be increased when Aclidinium is combined with Rimiterol.
Adenosine	The risk or severity of Tachycardia can be increased when Adenosine is combined with Rimiterol.
Alclofenac	The risk or severity of hypertension can be increased when Alclofenac is combined with Rimiterol.
Alfentanil	The risk or severity of hypertension can be increased when Alfentanil is combined with Rimiterol.
Alfuzosin	The therapeutic efficacy of Rimiterol can be decreased when used in combination with Alfuzosin.
Aliskiren	Rimiterol may decrease the antihypertensive activities of Aliskiren.

Improve patient outcomes

Build effective decision support tools with the industry’s most comprehensive drug-drug interaction checker.

Learn more

Food Interactions

Not Available

Chemical Identifiers

UNII: 26GIW6ZLPH
CAS number: 32953-89-2
InChI Key: IYMMESGOJVNCKV-JOYOIKCWSA-N
InChI: InChI=1S/C12H17NO3/c14-10-5-4-8(7-11(10)15)12(16)9-3-1-2-6-13-9/h4-5,7,9,12-16H,1-3,6H2/t9-,12+/m0/s1
IUPAC Name: 4-[(R)-hydroxy[(2S)-piperidin-2-yl]methyl]benzene-1,2-diol
SMILES: O[C@@H]([C@@H]1CCCCN1)C1=CC(O)=C(O)C=C1

References

General References

Not Available

External Links

ChemSpider: 24673379
RxNav: 9388
ChEMBL: CHEMBL1097630
ZINC: ZINC000001565247
Wikipedia: Rimiterol

Clinical Trials

Clinical Trials

Phase	Status	Purpose	Conditions	Count

Pharmacoeconomics

Manufacturers: Not Available
Packagers: Not Available
Dosage Forms: Not Available
Prices: Not Available
Patents: Not Available

Properties

State

Not Available

Experimental Properties

Not Available

Predicted Properties

Property	Value	Source
Water Solubility	6.83 mg/mL	ALOGPS
logP	-0.08	ALOGPS
logP	0.44	ChemAxon
logS	-1.5	ALOGPS
pKa (Strongest Acidic)	9.74	ChemAxon
pKa (Strongest Basic)	8.93	ChemAxon
Physiological Charge	1	ChemAxon
Hydrogen Acceptor Count	4	ChemAxon
Hydrogen Donor Count	4	ChemAxon
Polar Surface Area	72.72 Å²	ChemAxon
Rotatable Bond Count	2	ChemAxon
Refractivity	61.04 m³·mol^-1	ChemAxon
Polarizability	23.79 Å³	ChemAxon
Number of Rings	2	ChemAxon
Bioavailability	1	ChemAxon
Rule of Five	Yes	ChemAxon
Ghose Filter	Yes	ChemAxon
Veber's Rule	No	ChemAxon
MDDR-like Rule	No	ChemAxon

Predicted ADMET Features

Not Available

Spectra

Mass Spec (NIST)

Not Available

Spectra

Spectrum	Spectrum Type	Splash Key
Predicted GC-MS Spectrum - GC-MS	Predicted GC-MS	Not Available
Predicted MS/MS Spectrum - 10V, Positive (Annotated)	Predicted LC-MS/MS	Not Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)	Predicted LC-MS/MS	Not Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)	Predicted LC-MS/MS	Not Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)	Predicted LC-MS/MS	Not Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)	Predicted LC-MS/MS	Not Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)	Predicted LC-MS/MS	Not Available

Drug created on June 23, 2017 20:44 / Updated on February 21, 2021 18:54

Rimiterol

Identification

Structure for Rimiterol (DB13559)

Pharmacology

Interactions

Categories

Chemical Identifiers

References

Clinical Trials

Pharmacoeconomics

Properties

Spectra